Pharmaceutical giant GlaxoSmithKline (GSK) has clarified its earlier statement over the firm’s exit from Kenya amid the global overhaul of the multinational.
The firm, which mainly deals in prescription drugs and vaccines business, reiterated that it was exiting Kenya and instead adopt a distributor-led model to supply the country with its products.
